{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-095776","form_type":"8-K","ticker":"CERO","cik":"0001870404","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2026-08-31T20:52:35+00:00","discovered_at":"2026-08-31T20:53:17.341087+00:00","generated_at":"2026-08-31T20:53:30.021137+00:00","sec_items":["1.01","1.02","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CERo Therapeutics secures up to $11.67M senior secured note with SRX Global","bullets":["Consolidates prior notes of $5,666,108.77 (SRX $2,794,000; Keystone $2,872,108.77) plus up to $6M additional advances.","Initial advance of $775,665 on Aug 27, 2026; proceeds for trade payables and working capital.","10% annual interest (24.99% on default); matures Oct 15, 2026; secured by subsidiary stock and all assets.","Subsidiary CERo Therapeutics, Inc. guarantees payment; collateral includes IP, patents, CER-1236 assets."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-095776","json":"https://secwatch.observer/filing/0001213900-26-095776.json","markdown":"https://secwatch.observer/filing/0001213900-26-095776.md","text":"https://secwatch.observer/filing/0001213900-26-095776.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026095776/0001213900-26-095776-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026095776/ea0304037-8k_cero.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-31T20:53:30.021137+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}